Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Hepatology

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.22598PMID 19085908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efectividad del tratamiento de la hepatitis C con peginterferón alfa (2a o 2b) más ribavirina en pacientes naïve

  2008cited by this paper
• 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY

  2008cited by this paper
• Incidence of anaemia and impact on sustained virological response in HIV/HCV‐coinfected patients treated with pegylated interferon plus ribavirin

  2008cited by this paper
• 990 PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN VERSUS PEGINTERFERON ALPHA-2B PLUS RIBAVIRIN IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS OF A PROSPECTIVE RANDOMISED TRIAL

  2008cited by this paper
• [Effectiveness of peginterferon alpha-2a or -2b plus ribavirin in naïve patients with hepatitis C infection].

  2008cited by this paper
• Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin

  2007cited by this paper
• Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial

  2007cited by this paper
• Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection

  2007cited by this paper
• Peginterferon alpha‐2b plus ribavirin vs interferon alpha‐2b plus ribavirin for chronic hepatitis C in HIV‐coinfected patients

  2007cited by this paper
• Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients

  2007cited by this paper
• Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin

  2007cited by this paper
• A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

  2006cited by this paper
• Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens

  2005cited by this paper
• Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

  2005cited by this paper
• Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart

  2005cited by this paper
• A Comparison of Sustained Viral Response in Patients with Chronic Hepatitis C Virus (HCV) Treated with Peginterferon Alfa-2a (Peg2a) Versus Peginterferon Alfa-2b (Peg2b) and Ribavirin: 325

  2005cited by this paper
• Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

  2004cited by this paper
• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  2004cited by this paper
• Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

  2004cited by this paper
• Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients.

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

  2004cited by this paper
• Hepatitis C in the HIV-Infected Person

  2003cited by this paper
• Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.

  2003cited by this paper
• Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.

  2002cited by this paper
• Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

  2001cited by this paper
• Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

  2001cited by this paper
• Determination of Hepatitis C Virus Genotype by Direct Sequence Analysis of Products Generated with the Amplicor HCV Test

  1999cited by this paper
• Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

  1999cited by this paper
• Classification of chronic viral hepatitis: a need for reassessment.

  1991cited by this paper
• Métodos Estadísticos para Investigadores

  1961cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis

  2021cites this paper
• Coinfection of Hepatitis B and C in HIV Patients: A Review of the State of the Art

  2020cites this paper
• Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

  2019cites this paper
• Hepatitis C and HIV Coinfection in Developing Countries

  2018cites this paper
• Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis

  2017influential citation
• Treatment of Hepatitis C Virus Infection in the HIV- Infected Patients by Pegylated Interferon and Ribavirin in Tehran, Iran

  2017cites this paper
• Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital.

  2017cites this paper
• Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.

  2016cites this paper
• HIV and HCV Therapies in 2016: Optimal Regimens.

  2016cites this paper
• The effect of the degree of hepatitis C-related fibrosis on the responsiveness to pegylated interferon &agr;-2a versus pegylated interferon &agr;-2b: Egyptian study

  2016cites this paper
• Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection

  2016cites this paper
• Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV‐coinfected patients

  2015cites this paper
• Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person

  2015cites this paper
• A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

  2015cites this paper
• Efecto del tratamiento antirretroviral en la respuesta virológica a interferón pegilado y ribavirina en pacientes coinfectados por el virus de la inmunodeficiencia humana y el virus de la hepatitis C

  2015influential citation
• Natural history and treatment of Hepatitis C/HIV coinfection: is it time to change paradigms?

  2015cites this paper
• The interferon-alpha revival in CML

  2015cites this paper
• Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study

  2015cites this paper
• Comparison of Haematologic Side Effects of Different Pegylated Interferon-α Molecules Combined With Ribavirin

  2015cites this paper
• Virus de la Hepatitis C: estado actual de los aspectos genéticos, clínicos y epidemiológicos

  2015cites this paper
• Cytopenias during Treatment of HIV–HCV-Coinfection with Pegylated Interferon and Ribavirin: Safety Analysis of the OPERA Study

  2015influential citation
• Role of liver transplantation in human immunodeficiency virus positive patients.

  2015cites this paper
• Faldaprevir and pegylated interferon &agr;-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

  2015cites this paper
• The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study

  2014cites this paper
• Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new

  2014cites this paper
• Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study)

  2014cites this paper
• Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

  2014cites this paper
• Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV–HIV Coinfection in Interferon-Naive Patients

  2014cites this paper
• Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management

  2014influential citation
• HCV and HIV co-infection: mechanisms and management

  2014cites this paper
• Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues

  2014cites this paper
• Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database

  2014cites this paper
• Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3

  2014cites this paper
• LIJEČENJE KRONIČNOG HEPATITISA C U OSOBA ZARAŽENIH VIRUSOM HUMANE IMUNODEFICIJENCIJE

  2014cites this paper
• Supplemental Digital Content 1

  2014cites this paper
• Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA*

  2013cites this paper
• The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus

  2013cites this paper
• Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

  2013influential citation
• The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study

  2013cites this paper
• Optimizing treatment in HIV/HCV coinfection.

  2013cites this paper
• Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.

  2013cites this paper
• Hepatitis C Virus Infection: Looking for Interferon Free Regimens

  2013cites this paper
• Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation.

  2013cites this paper
• Antiviral therapy for “difficult‐to‐treat” hepatitis C virus‐infected patients

  2013cites this paper
• Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment

  2013cites this paper
• The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients

  2013cites this paper
• Ocular surface neoplasias and human immunodeficiency virus infection

  2013cites this paper
• [Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].

  2013cites this paper
• Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon.

  2013cites this paper
• Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

  2013cites this paper
• Hepatitis in persons infected with HIV.

  2013cites this paper
• Pegylated Interferon-a2a and Ribavirin versus Pegylated Interferon-a2b and Ribavirin in Chronic Hepatitis C

  2013cites this paper
• Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the

  2013cites this paper
• [Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].

  2013cites this paper
• Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell’epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0–F2

  2013cites this paper
• Meta‐analysis: pegylated interferon α‐2a achieves higher early virological responses than α‐2b in chronic hepatitis C

  2013cites this paper
• Sustained Virological Response and Baseline Predictors in HIV-HCV Coinfected Patients Retreated with Pegylated Interferon and Ribavirin after Failing a Previous Interferon-Based Therapy: Systematic Review and Meta-Analysis

  2013cites this paper
• Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production.

  2012cites this paper
• Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users

  2012influential citation
• [Evaluation of the costs of transient elastography (FibroScan(®)) in the diagnosis of liver fibrosis in HIV patients with hepatitis C virus].

  2012cites this paper
• HIV and viral hepatitis coinfections: advances and challenges

  2012cites this paper
• Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C

  2012cites this paper
• Evaluación económica de la elastografía de transición (FibroScan ®) en el diagnóstico de fibrosis hepática en pacientes con hepatitis C coinfectados con VIH

  2012cites this paper
• Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

  2012cites this paper
• Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient

  2012cites this paper
• Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

  2012cites this paper
• Treatment with Interferon and Ribavirin

  2012cites this paper
• Antiviral Drugs and the Treatment of Hepatitis C

  2012cites this paper
• Hepatitis C virus‐human immunodeficiency virus coinfection

  2012cites this paper
• APASL consensus statements and management algorithms for hepatitis C virus infection

  2012cites this paper
• HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment

  2012cites this paper
• Pegylated Interferons for the Treatment of Chronic Hepatitis C

  2012cites this paper
• Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

  2012cites this paper
• Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.

  2012cites this paper
• The Role of Liver Transplantation in HIV Positive Patients

  2012cites this paper
• Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants

  2012influential citation
• Reply:

  2011cites this paper
• Reply:

  2011cites this paper
• Abacavir Coadministration Does Not Interfere with the Suppressive Activity of Ribavirin in An HCV Replicon System

  2011cites this paper
• Interferon combination therapy for HIV/hepatitis C virus coinfection.

  2011cites this paper
• Reply:

  2011cites this paper
• Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection—21 plus 13

  2011cites this paper
• Liver transplantation in human immunodeficiency virus‐positive patients

  2011cites this paper
• Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C

  2011cites this paper
• Comment on a systematic review of randomized trials of peginterferon alpha‐2a versus peginterferon alpha‐2b in chronic hepatitis C

  2011cites this paper
• Marcadores farmacogenéticos como factores predictivos de respuesta al tratamiento del VHC en pacientes VIH

  2011cites this paper
• Reply:

  2011cites this paper
• Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

  2011cites this paper
• [Treatment of hepatitis C virus in HIV-positive patients].

  2011cites this paper
• Reply:

  2011cites this paper
• Current treatment of choice for chronic hepatitis C infection

  2011cites this paper
• Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus: Challenges and Therapeutic Advances

  2011cites this paper
• Genotype 1: Standard Treatment

  2011cites this paper
• Reply:

  2011cites this paper
• Increasing burden of liver disease in patients with HIV infection.

  2011cites this paper
• Interferon alpha for treatment of chronic myeloid leukemia.

  2011cites this paper
• Reply:

  2010cites this paper
• Reply:

  2010cites this paper
• The Comparative Efficacy and Safety of Peginterferon Alpha-2 a vs . 2 b for the Treatment of Chronic HCV Infection : A Meta-Analysis

  2010cites this paper